Cargando…
Assessing the efficacy and safety of Craniosacral therapy for migraine: A single center randomized controlled trial
OBJECTIVE: Design a feasible study to assess the efficacy and safety of Craniosacral therapy (CST) in the treatment of migraine, using a rigorous and innovative randomized controlled study design involving complementary light-touch sham treatments (CLST) as an attention control intervention. METHODS...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637508/ https://www.ncbi.nlm.nih.gov/pubmed/37960717 http://dx.doi.org/10.1097/MD.0000000000035431 |
_version_ | 1785146513150705664 |
---|---|
author | Jiang, Guangya Ma, Saichao Zhao, Jinfeng Zhang, Ming Li, Yan Chen, Wenli Cui, Lin Jia, Liuyun |
author_facet | Jiang, Guangya Ma, Saichao Zhao, Jinfeng Zhang, Ming Li, Yan Chen, Wenli Cui, Lin Jia, Liuyun |
author_sort | Jiang, Guangya |
collection | PubMed |
description | OBJECTIVE: Design a feasible study to assess the efficacy and safety of Craniosacral therapy (CST) in the treatment of migraine, using a rigorous and innovative randomized controlled study design involving complementary light-touch sham treatments (CLST) as an attention control intervention. METHODS: This was a single-center, randomized, cross-over placebo-controlled experimental design. A total of 87 participants who suffered migraine attacks from 4 to 9 per month were randomly assigned into either 2 weekly units of CST or CLST for 4 weeks. And then the 2 groups were crossed and continued treatment for 4 weeks plus a follow-up observation for 4 weeks. As the primary outcome measures, Headache Impact Test-6 (HIT-6) and headache frequency were assessed every 4 weeks (at baseline, week 4, week 8 and week 12). The secondary outcome was the scores of Headache Disability inventory (HDI) and the Hamilton Anxiety Scale (HAMA) as well as the adverse events. RESULTS: All 87 individuals had been screened for eligibility, of which 60 were licensed for the study. The difference of HIT-6 and headache frequency between the 2 groups was not significant at the baseline. But the headache frequency and HIT-6 of 2 groups were all declined respectively after the CST at week 4 (group A) and week 8 (group B) than before (P(☆)= 0.01 < 0.05, 95% CI, −3.06 to −1.87; P(※)= 0.01 < 0.05, 95% CI, −3.52 to −2.53; P(1A) = 0.01 < 0.05, 95% CI, 4.55–11.7; P(2B) = 0.01 < 0.05, 95% CI, −11.78 to −6.01) while the changes were not obvious after CLST with previous treatment. The scores and frequency of fourth evaluation showed that there was no significant increase or decrease in both the 2 groups. Besides, we found that the mean scores of HIT-6 for all participants, compared with the baseline, were decreased significantly after the 3 round treatments (P(3A) = 0.01 < 0.05, 95% CI, −13.12 to −6.4; P(3B) = 0.01 < 0.05, CI, −12.73 to −6.69). We also showed the similar result in the scores of HDI and HAMA. CONCLUSION: The results indicated that standardized CST was both effective and safe in alleviating the migraine intensity and frequency as well as the headache-related disability. Further larger research is needed. |
format | Online Article Text |
id | pubmed-10637508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-106375082023-11-15 Assessing the efficacy and safety of Craniosacral therapy for migraine: A single center randomized controlled trial Jiang, Guangya Ma, Saichao Zhao, Jinfeng Zhang, Ming Li, Yan Chen, Wenli Cui, Lin Jia, Liuyun Medicine (Baltimore) 5300 OBJECTIVE: Design a feasible study to assess the efficacy and safety of Craniosacral therapy (CST) in the treatment of migraine, using a rigorous and innovative randomized controlled study design involving complementary light-touch sham treatments (CLST) as an attention control intervention. METHODS: This was a single-center, randomized, cross-over placebo-controlled experimental design. A total of 87 participants who suffered migraine attacks from 4 to 9 per month were randomly assigned into either 2 weekly units of CST or CLST for 4 weeks. And then the 2 groups were crossed and continued treatment for 4 weeks plus a follow-up observation for 4 weeks. As the primary outcome measures, Headache Impact Test-6 (HIT-6) and headache frequency were assessed every 4 weeks (at baseline, week 4, week 8 and week 12). The secondary outcome was the scores of Headache Disability inventory (HDI) and the Hamilton Anxiety Scale (HAMA) as well as the adverse events. RESULTS: All 87 individuals had been screened for eligibility, of which 60 were licensed for the study. The difference of HIT-6 and headache frequency between the 2 groups was not significant at the baseline. But the headache frequency and HIT-6 of 2 groups were all declined respectively after the CST at week 4 (group A) and week 8 (group B) than before (P(☆)= 0.01 < 0.05, 95% CI, −3.06 to −1.87; P(※)= 0.01 < 0.05, 95% CI, −3.52 to −2.53; P(1A) = 0.01 < 0.05, 95% CI, 4.55–11.7; P(2B) = 0.01 < 0.05, 95% CI, −11.78 to −6.01) while the changes were not obvious after CLST with previous treatment. The scores and frequency of fourth evaluation showed that there was no significant increase or decrease in both the 2 groups. Besides, we found that the mean scores of HIT-6 for all participants, compared with the baseline, were decreased significantly after the 3 round treatments (P(3A) = 0.01 < 0.05, 95% CI, −13.12 to −6.4; P(3B) = 0.01 < 0.05, CI, −12.73 to −6.69). We also showed the similar result in the scores of HDI and HAMA. CONCLUSION: The results indicated that standardized CST was both effective and safe in alleviating the migraine intensity and frequency as well as the headache-related disability. Further larger research is needed. Lippincott Williams & Wilkins 2023-11-10 /pmc/articles/PMC10637508/ /pubmed/37960717 http://dx.doi.org/10.1097/MD.0000000000035431 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 5300 Jiang, Guangya Ma, Saichao Zhao, Jinfeng Zhang, Ming Li, Yan Chen, Wenli Cui, Lin Jia, Liuyun Assessing the efficacy and safety of Craniosacral therapy for migraine: A single center randomized controlled trial |
title | Assessing the efficacy and safety of Craniosacral therapy for migraine: A single center randomized controlled trial |
title_full | Assessing the efficacy and safety of Craniosacral therapy for migraine: A single center randomized controlled trial |
title_fullStr | Assessing the efficacy and safety of Craniosacral therapy for migraine: A single center randomized controlled trial |
title_full_unstemmed | Assessing the efficacy and safety of Craniosacral therapy for migraine: A single center randomized controlled trial |
title_short | Assessing the efficacy and safety of Craniosacral therapy for migraine: A single center randomized controlled trial |
title_sort | assessing the efficacy and safety of craniosacral therapy for migraine: a single center randomized controlled trial |
topic | 5300 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637508/ https://www.ncbi.nlm.nih.gov/pubmed/37960717 http://dx.doi.org/10.1097/MD.0000000000035431 |
work_keys_str_mv | AT jiangguangya assessingtheefficacyandsafetyofcraniosacraltherapyformigraineasinglecenterrandomizedcontrolledtrial AT masaichao assessingtheefficacyandsafetyofcraniosacraltherapyformigraineasinglecenterrandomizedcontrolledtrial AT zhaojinfeng assessingtheefficacyandsafetyofcraniosacraltherapyformigraineasinglecenterrandomizedcontrolledtrial AT zhangming assessingtheefficacyandsafetyofcraniosacraltherapyformigraineasinglecenterrandomizedcontrolledtrial AT liyan assessingtheefficacyandsafetyofcraniosacraltherapyformigraineasinglecenterrandomizedcontrolledtrial AT chenwenli assessingtheefficacyandsafetyofcraniosacraltherapyformigraineasinglecenterrandomizedcontrolledtrial AT cuilin assessingtheefficacyandsafetyofcraniosacraltherapyformigraineasinglecenterrandomizedcontrolledtrial AT jialiuyun assessingtheefficacyandsafetyofcraniosacraltherapyformigraineasinglecenterrandomizedcontrolledtrial |